Cellevate appoints Jennifer Valdes as VP Sales & Marketing North America to drive U.S. expansion
LUND, Sweden, December 9, 2024 – Cellevate an innovative biotech company commercializing next-generation cell culture systems that revolutionize biomanufacturing productivity, is pleased to announce the appointment of Jennifer Valdes as Vice President of Sales & Marketing for the North American market.
Jennifer Valdes has over 15 years experience executing effective sales strategies in the biopharmaceutical manufacturing arena, leveraging a hands-on approach to foster customer relationships and drive revenue growth. With a technical background in molecular microbiology, she has held various regional and global strategic sales positions at Sartorius, and most recently served as OEM Sales Manager for Western US at SaniSure.
Jennifer Valdes holds a Master of Science in Cell and Molecular Biology.
“I’m incredibly excited to join Cellevate at such a key time, as we are bringing Cellevat3d® nanofiber-based cell culture systems to the U.S. market”, said Jennifer Valdes, VP Sales & Marketing US of Cellevate. “This innovative technology provides the solution to many of the challenges in upstream bioprocessing, especially for cell and gene therapy, and I look forward to working closely with our leadership teams to achieve the milestones that will fuel our expansion and success”.
“We are thrilled to welcome Jennifer Valdes to the Cellevate team,” said Laura Chirica, CEO of Cellevate. “Jennifer’s extensive experience and deep understanding of the biopharma and biotech industries, combined with her collaborative leadership style will be invaluable in driving Cellevate’s success and growth in the US market. She will play a key role in advancing the commercialization of our Cellevat3d® nanofiber-based cell culture systems in viral vector biomanufacturing. Additionally, her insights will help strengthen partnerships with key opinion leaders and strategic collaborators.”
This strategic appointment marks a significant milestone in Cellevate’s mission to expand its U.S. footprint and commercialize cutting-edge solutions to the biomanufacturing industry.
For more information, please contact:
Laura Chirica, PhD
CEO Cellevate
Email: laura.chirica@cellevate.com
About Cellevate
Cellevate is a Swedish biotech company based on proprietary nanofiber technology dedicated to building the next generation cell culture systems for cell- and gene therapy and novel vaccines biomanufacturing. The core nanotechnology, Cellevat3d® is a sustainable, deep-tech innovation for the biopharmaceutical industry. This platform allows for an industrial-scale production of a new category of nanofiber cell culture systems – with unparalleled surface area for cell growth, reproducibility, customization, and scalability, which ultimately lead to increased yield, productivity and process economy. Cellevat3d® nanofiber-based products are designed and validated as an integrated part of upstream bioprocessing solutions, from laboratory to large-scale production.
For more information, please visit www.cellevate.com.
